A New Medication Class for Weight and Metabolic Health
The most recent medication to be approved by the TGA for weight management in Australia is a combined GLP-1 and GIP receptor agonist — a dual incretin therapy that works on two separate hormone pathways involved in appetite regulation and metabolic control.
This medication class had already been approved in Australia for over a year for the treatment of Type 2 Diabetes before receiving its weight management indication — meaning its safety and efficacy profile was well established before its broader use.
How GLP-1 and GIP Receptor Agonists Work
GIP and GLP-1 receptor agonists work by activating two incretin hormone receptors simultaneously. GLP-1 is a well-established regulator of appetite and caloric intake. Clinical evidence suggests that the addition of GIP activity may further contribute to appetite regulation — potentially producing greater weight loss than GLP-1 agonism alone.
In plain terms: these medications help reduce hunger and food intake through hormone pathways, rather than through willpower or restriction alone. The body's own biology is engaged to support weight loss.
The Impact on Diabetes Risk
One of the most significant findings from clinical trials is the effect of this medication on the risk of progressing to Type 2 Diabetes. In adults with overweight or obesity and pre-diabetes, the drug reduced the risk of developing Type 2 Diabetes by 94% compared to placebo.
For patients living with obesity and elevated metabolic risk, this is a genuinely remarkable outcome. The ability to interrupt the progression from pre-diabetes to Type 2 Diabetes — a condition with lifelong consequences — represents a significant step forward in metabolic disease management.
What This Means for Patients
For many patients, the fear of developing Type 2 Diabetes — with its associated risks of cardiovascular disease, kidney disease, and nerve damage — is a significant motivator for seeking treatment. Evidence that effective weight loss treatment can dramatically reduce this risk strengthens the case for early, proactive intervention.
If you have been told you are at risk of Type 2 Diabetes and are living with overweight or obesity, speak to your doctor about whether medical weight loss treatment may be appropriate for you. Our doctors at MedSurg Weight Loss can assess your individual risk and discuss the full range of evidence-based options available.
Medical disclaimer: This article summarises published clinical research and is for general informational purposes only. It does not constitute medical advice. Treatment suitability varies between individuals — please consult your doctor to discuss whether medical weight loss medication is appropriate for your circumstances.